Why the study?
What are the pharmacokinetics and safety of intraperitoneal doxorubicin in patients with abdominopelvic malignancies?
Population
12 patients with malignant disease in the abdominopelvic space
Design
Case_series
Authors
Loading...
Local toxicity likely restricts IP doxorubicin to minimal disease; leaves open its efficacy and safety in controlled trials.
What are the pharmacokinetics and safety of intraperitoneal doxorubicin in patients with abdominopelvic malignancies?
Intraperitoneal doxorubicin can be administered at moderate concentrations, but its usefulness is likely limited to patients with minimal abdominal disease due to local toxicity.
Demicheli et al. (1985) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: